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High-sensitivity cardiac troponin is central to the diagnosis of myocardial
infarction when measured in patients with signs or symptoms consistent
with myocardial ischaemia. In this context, the Universal Definition of
Myocardial Infarction (UDMI) mandates a rise and/or fall in troponin
concentrations with at least one measure above the 99th centile of a
healthy reference population.1 Increasing precision of cardiac troponin
assays has allowed quantification of ever lower concentrations in the
bloodstream, with detectable circulating levels present in over half of the
healthy population.2 Where previous diagnostic thresholds were limited
by assay precision, the 99th centile defines myocardial infarction by non-
conformity with the healthy state at a population level. However, this ap-
proach is subject to inconsistencies according to the gender balance, eth-
nicity, and stringency of screening for disease within reference
populations.3 Such controversies may have limited implementation of
high-sensitivity assays and the full recommendations of the UDMI.4
While lowering the diagnostic threshold for myocardial infarction has
previously been shown to improve patient outcomes,5 many clinicians
fear that increasingly sensitive assays may compromise specificity, as low
levels of cardiac troponin may be released in the absence of acute plaque
rupture and coronary thrombosis, the hallmarks of a type 1 myocardial
infarction.6 Until recently there have been no randomized trials of the
UDMI or the introduction of high-sensitivity troponin assays, with guid-
ance based solely on expert consensus and observational data.
The High-STEACS trial
The High-Sensitivity Troponin in the Evaluation of patients with sus-
pected Acute Coronary Syndrome (High-STEACS) cluster-randomized
controlled trial assessed the impact of introducing a high-sensitivity car-
diac troponin I (hs-cTnI) assay with sex-specific 99th centile diagnostic
thresholds (16 ng/L in females, 34 ng/L in males).7 The study included 48
282 consecutive patients in whom cardiac troponin was requested for
suspected acute coronary syndrome across 10 hospitals in Scotland.
Contemporary and hs-cTnI assays were run concurrently in two phases
of the study: a validation phase in which the contemporary assay was
used to guide clinical decisions and the hs-cTnI results were suppressed,
and an implementation phase where this process was reversed and
sex-specific 99th centile thresholds of the hs-cTnI assay were used to
guide clinical care. Hospital sites were randomized to early or late imple-
mentation of hs-cTnI for clinical care. The primary endpoint of the trial
was subsequent myocardial infarction or cardiovascular death at 1 year
after initial hospital presentation. All events were independently adjudi-
cated against UDMI criteria by two physicians using all available clinical
information; disagreements were resolved by a third adjudicator.
The study population included 10 360 (21%) patients with hs-cTnI
concentrations above sex-specific 99th centile thresholds, of whom
1771 (4%) patients were reclassified only through use of the
high-sensitivity assay (i.e. concentrations above the 99th centile on high-
sensitivity testing but below the diagnostic threshold of the contempo-
rary troponin assay). Primary endpoint events did not vary between
those reclassified in the validation and implementation phases of the
study [15% vs. 12% respectively, adjusted odds ratio 1.10, 95% confi-
dence interval (95% CI) 0.75–1.61, P= 0.62]. Patients reclassified by hs-
cTnI were older than those identified by the contemporary test (mean
age 75± 14 vs. 70 ± 15 years old) and 83% were female, reflecting in part
the lower sex-specific 99th centile in women. Only one-third of those
reclassified by hs-cTnI received an adjudicated diagnosis of type 1 myo-
cardial infarction, compared to 60% of those identified by the contempo-
rary assay.
Implications for clinical practice
Previous improvements in outcomes achieved by increasingly sensitive
cardiac troponin assays5 were not replicated following introduction of
hs-cTnI assays and the 99th centile diagnostic threshold. This was despite
reclassified patients having a similar cardiac risk profile to those identified
by the contemporary assay and more than 1 in 9 reclassified patients sus-
taining a subsequent myocardial infarction or cardiac death within a year
of index hospital presentation. There are several possible reasons for
these observations. Two-thirds of reclassified patients did not sustain a
type 1 myocardial infarction where evidence-based therapy exists to im-
prove outcomes. Even including those with type 1 events, new second-
ary prevention therapy or coronary angiography was undertaken in
fewer than 1 in 10 reclassified patients after implementation of the new
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assay, limiting the potential to improve outcomes. This may be related to
the gender imbalance of reclassified patients, with several previous stud-
ies observing women receiving fewer investigations and treatments for
heart disease than men.8,9
The High-STEACS trial represents a challenge to the research field
and fundamentally questions the current approach to the diagnosis of
myocardial infarction. This should not prompt rejection of hs-cTnI
assays, which are highly specific markers of myocardial injury and have
major potential to improve patient care. This is demonstrated in the ef-
fective adoption of pathways for the rapid exclusion of myocardial infarc-
tion using low troponin concentrations well below the 99th centile, only
measureable using high-sensitivity assays.10–12 Such low-level concentra-
tions also have an emerging role in the estimation of future cardiovascu-
lar risk.13,14 It is clear that elevations of cardiac troponin must be central
to the diagnosis of myocardial infarction as objective evidence of myo-
cardial necrosis. However, assessment against a binary 99th centile
threshold may be too simplistic and ignore the information provided by
a continuous marker of myocardial injury.15
We argue that new approaches should be considered to support clini-
cians assessing patients with suspected acute coronary syndrome. In the
absence of gold-standard invasive coronary imaging, the evaluation of
type 1 myocardial infarction is a probabilistic evaluation of troponin con-
centrations in the context of patient signs, symptoms, electrocardio-
graphic, non-invasive, and invasive imaging. With appropriate statistical
modelling using large consecutive patient cohort studies such as High-
STEACS, established cardiovascular risk factors and high-sensitivity tro-
ponin measures can be combined to estimate the positive predictive
value for the diagnosis of type 1 myocardial infarction in an individual. In
a low-risk setting, the negative predictive value of low troponin concen-
trations may guide early safe exclusion of a cardiac event. This approach
has been adopted in the recently described myocardial-ischaemic-injury-
index (MI3), which uses a machine-learning algorithm trained across mul-
tiple international cohorts to predict the risk of type 1 myocardial infarc-
tion in an individual from their age, sex, and serial cardiac troponin
concentrations.16
The role of cardiac troponin in the assessment of patients with sus-
pected acute coronary syndrome is evolving. The precision of high-
sensitivity assays at very low troponin concentrations enable the use of
separate risk stratification and diagnostic thresholds for the evaluation of
patients with suspected acute coronary syndrome. We have previously
demonstrated the safety and effectiveness of a risk stratification thresh-
old at 5 ng/L for the exclusion of myocardial infarction.10,17 The diagnos-
tic threshold remains at the 99th centile in the 4th UDMI,1 but modelling
may allow individual refinement of risk based on additional clinical char-
acteristics. Additional blood biomarkers may improve diagnostic discrim-
ination, such as in distinguishing between myocardial injury secondary to
active coronary disease from left ventricular hypertrophy or systolic dys-
function. Further research is ongoing and much needed in this area.15
Between the low-risk stratification and diagnostic thresholds are
patients at intermediate risk, where the optimum treatment pathway is
uncertain. The SCOT-HEART trial suggested that CT coronary angiog-
raphy (CTCA) could improve targeting of therapy and long-term out-
comes in patients with stable angina by identification of underlying
coronary artery disease.18 We are prospectively assessing the role of
CTCA for this intermediate-risk group with suspected acute coronary
syndrome, in whom myocardial infarction has been excluded, as part of
the Troponin in Acute chest pain to Risk stratify and Guide EffecTive use
of Computed Tomography Coronary Angiography (TARGET-CTCA)
randomized controlled trial (clinicaltrials.gov NCT03952351).
In conclusion, the High-STEACS trial is the first randomized trial to
evaluate the impact of adopting the UDMI and 99th centile diagnostic
threshold in practice. Introduction of hs-cTnI increased the diagnosis of
myocardial infarction but did not reduce the risk of subsequent myocar-
dial infarction or cardiac death. To improve the clinical utility of high-
sensitivity cardiac troponin in the assessment of patients with suspected
acute coronary syndrome, we suggest troponin should no longer be
considered a binary test. The use of separate risk stratification and diag-
nostic thresholds or probabilistic modelling could improve decisions in
individual patients, and such an approach now requires prospective eval-
uation in future clinical trials.
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